Dashboard
Overview of all specialty pharmacy program operations
48 cases stalled beyond SLA
Handoff delays detected across programs — review responsible parties
Active Cases
703
Across 10 programs
On Track
407
58% of active
Stalled
101
14% stall rate
Avg Time to Fill
18.4d
First fill average
Active Case Volume
Last 90 days
Stalled Cases Trend
Last 90 days
Programs
Velorantib
Oncology · Meridian Pharmaceuticals
91
Healthy
Nexuximab
Immunology · Aethon Biosciences
52
At Risk
Orathera
Rare Disease · Luminos Therapeutics
74
Needs Attention
Celvistro
Neurology · Meridian Pharmaceuticals
88
Healthy
Trelvara
Oncology · Aethon Biosciences
79
Needs Attention
Zenivex
Immunology · Solara Health
83
Healthy
Parvulex
Rare Disease · Luminos Therapeutics
71
Needs Attention
Axentria
Neurology · Solara Health
77
Needs Attention
Oritavex
Oncology · Luminos Therapeutics
85
Healthy
Brevunol
Immunology · Aethon Biosciences
80
Healthy
Recent Activity
REF-2025-0312·Velorantib
REF-2025-0488·Nexuximab
REF-2026-0017·Celvistro
REF-2025-0201·Orathera
REF-2025-0744·Trelvara
REF-2025-0156·Velorantib
REF-2025-0522·Nexuximab
REF-2025-0890·Zenivex
REF-2025-0334·Orathera
REF-2025-0667·Axentria
REF-2025-0445·Nexuximab
REF-2025-0178·Parvulex
REF-2025-0823·Oritavex
REF-2025-0091·Brevunol
REF-2025-0556·Nexuximab